Healthcare
We focus on high-potential startups in biotech and pharmaceuticals, med-tech, and digital health care industries, along with broader biomedical and healthcare service sectors.
Portfolio Companies
Discover the companies in which we are investing under this strategy
COMPANY
HEADQUARTERS
YEAR
PRODUCT
HEADQUARTERS
Taiwan
YEAR
2016
PRODUCT
Specialty pharmaceuticals
Handa Pharmaceuticals is a specialty pharmaceutical company with a proven track record of developing controlled-release prescription drugs that are difficult to formulate. Handa focuses on high value, high barrier oral abbreviated new drug application (ANDA) products and develops 505(b)(2) New Drug Applications (NDA) products utilizing dosage form/formulation expertise as well.
HEADQUARTERS
Taiwan
YEAR
2014
PRODUCT
New drug
Foresee Pharmaceuticals is a clinical-stage pharmaceutical company. Through its proprietary drug delivery technology, it has successfully developed and commercialized Camcevi, a long-acting injection drug for prostatic cancer. Meanwhile, it continues to develop first-in-class NCE in disease areas with highly unmet medical needs.
HEADQUARTERS
Taiwan
YEAR
2018
PRODUCT
Medical e-commerce platform
Med to Clinics is a subsidiary of Sharehope Medicine (8403 TT), known for its integration of the three largest medical information systems in Taiwan for the build-out of a B2B medical procurement cloud platform. The firm aims to cover 9,000 local clinics across Taiwan and provide brand new integrated procurement, inventory management and medical recommendation services to create win-win situations for clinics, pharmaceutical companies and patients.
HEADQUARTERS
Taiwan
YEAR
2018
PRODUCT
long-acting release drug products for opioid use disorder, chronic pain, and major depressive disorder
Alar Pharmaceuticals Inc. (6785 TT) is a new 505(b)(2) drug development company focused on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorders, chronic pains, and major depressive disorders.
HEADQUARTERS
Taiwan
YEAR
2016
PRODUCT
Stemchymal® allogeneic stem cells products
Steminent Biotherapeutics Inc. is a leading stem cell research and development company dedicated to the development of Stemchymal® allogeneic stem cells products. Its treatment of PolyQ Spinocerebellar Ataxia is a novel regenerative product in degenerative diseases.
HEADQUARTERS
USA
YEAR
2018
PRODUCT
Immunotherapies for cancer with myeloid checkpoint inhibitors
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors that have the potential to transform current treatment approaches for blood cancers and solid tumors.
HEADQUARTERS
Taiwan
YEAR
2020
PRODUCT
Leukocyte reduction filter
PuriBlood developed a unique technology for blood cell separation that is supported by a world-class research center – R&D center for membrane technology. PuriBlood is committed to improving the blood filtration process with innovative technology of "Zwitterionic-bias Surface Coating Technology (ZISC technology)”
HEADQUARTERS
Taiwan
YEAR
2020
PRODUCT
New drug research and development
Pharmosa Biopharm Inc.(6875 TT) develops existing drugs by exploiting innovative delivery formulations and medical devices, then bringing combined medicines to patients and healthcare providers. Its first new drug has entered phase III clinical trials and is expected to apply for FDA approval in two years.
HEADQUARTERS
USA/Taiwan
YEAR
2021
PRODUCT
Targeted, allogeneic, off-the-shelf cell therapies
Acepodia is a clinical-stage biotechnology company developing targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers of all types. Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and NgdT cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable, and safe. The Antibody-Conjugated Effector (ACE) cells significantly increase the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.
HEADQUARTERS
Taiwan
YEAR
2021
PRODUCT
Proprietary drug formulation platform, ADC biosimilars
Formosa Pharmaceuticals, Inc., is a biotech company with an emphasis on ophthalmology, oncology, and anti-infectives. Its proprietary nanoparticle formulation technology (APNT) operates on the principle of API particle size reduction and subsequent stable formulation and is applicable towards innovative 505(b)(2) and novel drug prospects.
HEADQUARTERS
Taiwan
YEAR
2021
PRODUCT
In vitro diagnostic devices in male fertility
Bonraybio is dedicated to developing in vitro diagnostic devices with AI-enabled, miniaturized, and automated optical microscopy. The total solution for male Infertility tests is currently exported to over 50 countries around the world under its own brand LensHooke®.
HEADQUARTERS
Switzerland
YEAR
2022
PRODUCT
cancer immunotherapies
Onward Therapeutics is a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer. Led by an experienced team in translational medicine and clinical development, Onward Therapeutics' pipelines is derived from multi-specific antibody platform and allogenic cell therapy technologies.
HEADQUARTERS
Taiwan
YEAR
2021
PRODUCT
Health management, health care products, genetic testing
Pregetic Medical Health Co., Ltd is the Subsidiary of ShareHope Medicine Inc. Pregetic Medical Health began by providing health screening services and has gradually expanded to provide digital health management services, health care products, and preventive medicine. Together with their strategic partners in finance and telecommunications, Pregetic Medical Health is building a comprehensive ecosystem for the health industry.
HEADQUARTERS
Taiwan
YEAR
2022
PRODUCT
Real-time sequencing technology for pathogen identification
Founded by a team of experts across a range of disciplines, Micronbrane Medical is a medical device star-up in Taiwan dedicated to developing precision medicine applications for clinical microbiology. Micronbrane Medical is working to improve microorganism detection times with their simpler, faster, and more affordable real-time sequencing technology that uses patented host depletion technology, allowing hospitals to identify pathogens within 24 hours.
HEADQUARTERS
Taiwan
YEAR
2022
PRODUCT
AI & CAD medical imaging software
TaiHao Medical is an artificial intelligence company developing medical imaging software. With certified and validated solutions for both handheld and automated breast ultrasound (ABUS), TaiHao aims to help medical professionals screen tumors more efficiently and manage increasing workloads.
HEADQUARTERS
USA/Taiwan
YEAR
2022
PRODUCT
Innovative 12-lead ECG device
QT Medical develops PCA500, a compact, user-friendly, medical-grade resting 12-lead ECG solution, with innovative prepositioned electrode strips and cloud-based storage and computation. With high precision, it has been approved for medical use in the US, EU, Taiwan, etc., to support decentralized trials, aviation medicine, emergency care, and telehealth across various healthcare domains.
HEADQUARTERS
Taiwan
YEAR
2023
PRODUCT
Engineered mesenchymal stem cell therapies, cell therapy CDMO
Taiwan Bio develops engineered mesenchymal stem cell therapies and also provides clinical manufacturing and analytical development services.
HEADQUARTERS
Taiwan
YEAR
2023
PRODUCT
Microarray patch
Win Coat Corporation developed the advanced multi-layer microarray patch technology platform known as WINMAPTM. With its stable needle structure and precise drug release control, WINMAPTM offers versatile applications in cosmetics, medical materials, pharmaceuticals, and vaccines.
HEADQUARTERS
Wuhan
YEAR
2020
PRODUCT
Development of medicine for central nervous system disorders
XWPharma is a new drug development company with an emphasis on the clinical stage. The company capitalizes on its three new drug R&D platforms to design and develop new drugs for central nervous system disorders. It specializes in chemically engineering products that have already hit the market or have proven to be effective, turning them into the best-in-class in the same indication field.
HEADQUARTERS
Suzhou
YEAR
2020
PRODUCT
Best-in-class and first-in-class new drug development
Founded in 2016, Sinovent is a clinical stage company addressing unmet medical needs and developing innovative best-in-class and first-in-class new drugs with global rights. It possesses 12 pipelines covering oncology, autoimmune, anti-infection and other therapeutic areas. From 2018 to 2020, it has been successively elected as the unicorn enterprise in Suzhou BioBay, and is preparing for the IPO on the SSE STAR Market.
HEADQUARTERS
Zhejiang Huzhou
YEAR
2021
PRODUCT
Small-molecule treatments of non-small cell lung cancer, etc.
TYK Medicines, Inc. was established in 2017 and positioned as an international innovative anti-cancer biotechnology company in China with a global vision. Its candidates of drugs focus on treatments of EGFR+ non-small cell lung cancer, ER+HER2- breast cancer and other diseases. Based on deuterium technology and multi-target drug development platforms, it can effectively derive innovative molecules with clinically validated pathways.
HEADQUARTERS
Shanghai
YEAR
2021
PRODUCT
AKT inhibitors
Laekna was founded in 2016 and headquartered in Zhangjiang, Shanghai with R&D and operations in the US and China. Laekna develops new targeted therapies to treat cancers and other diseases. It has collaborated with Novartis AG of Switzerland, obtaining global rights for 3 small-molecule tumor treatment candidates. Laekna continues their in-house R&D of new drugs and has advanced 3 drugs’ studies into Phase I/II clinical trials.
HEADQUARTERS
Kunshan
YEAR
2021
PRODUCT
Real-time diagnostic medical devices and reagents
Holosensor is a smart diagnostics company that integrates the R&D, manufacturing, sales and services of high-tech medical devices. Using microfluidic technology, Holosensor develops real-time diagnostic devices, chips, and reagents for smart diagnostics and equips micro and nano chips for diagnostics, automatic diagnostic instruments, and artificial intelligence algorithms. With a comprehensive product pipeline including cellular, molecular, and protein products, Holosensor is a leader in offering miniaturized, automated, accurate, and cloud-based smart solutions.
HEADQUARTERS
Kunshan
YEAR
2022
PRODUCT
Medical device CMO/CDMO
Founded in 2017 at its headquarters in Kunshan. MDHC Group is a high-tech enterprise dedicated to building a platform for lab consumables for minimally invasive surgery and life sciences. At the core of MDHC is a team who has mastered researching and developing products and materials for minimally invasive surgery and life sciences, allowing MDHC to become a leading CDMO (Contract Development and Manufacturing Organization) in the field.
HEADQUARTERS
USA
YEAR
2022
PRODUCT
Vascular Access Devices
Founded in 2015, Curatia Medical is headquartered in Sunnyvale, CA, U.S.A. and has a manufacturing operation in Suzhou. Curatia Medical is dedicated in developing, manufacturing, and selling disposables interventional medical devices for cardiac, neurology, and pulmonary departments. FDA, TUV and CFDA approved, Curatia Medical has passed multiple FDA and TUV SUD unannounced on-site audits. Currently its sales network covers more than 20 countries in North America, Europe, South America and Asia.
HEADQUARTERS
Baoding
YEAR
2023
PRODUCT
Biomanufacturing of high-quality natural ingredients
VDK focuses on sustainable, green and affordable biomanufacturing of high-quality natural ingredients. Relying on NaturaSyn technologies, VDK makes functional substances through microbial cell factories, solving a series of issues restricting production rate, quality and affordability of products from plant extraction. VDK reconstructs natural microorganisms to achieve the optimal yield and realize large-scale biomanufacturing in cell factories.
HEADQUARTERS
Luoyang
YEAR
2023
PRODUCT
Vascular Access Devices
SVision Imaging, Ltd was founded by a group of scientists and industry veterans of Silicon Valley in 2014 with a core mission to develop the most advanced ophthalmic technologies.
In 2019, SVision released the first Swept-Source Optical Coherence Tomography (OCT) device that combines deep imaging depth, rapid sweeping speed, extensive scan range, accurate lesion detection and Multimodal imaging capabilities. SVision will continue the innovation and push the limit of technologies. The product portfolios are extending from ophthalmic diagnostic devices to operational instruments. In doing so, SVision aims to empower ophthalmologists and benefit the patients worldwide.
In 2019, SVision released the first Swept-Source Optical Coherence Tomography (OCT) device that combines deep imaging depth, rapid sweeping speed, extensive scan range, accurate lesion detection and Multimodal imaging capabilities. SVision will continue the innovation and push the limit of technologies. The product portfolios are extending from ophthalmic diagnostic devices to operational instruments. In doing so, SVision aims to empower ophthalmologists and benefit the patients worldwide.
HEADQUARTERS
Beijing
YEAR
2023
PRODUCT
Ceramic Joints and Ceramic Oral Implant Materials
Arthrone Technology was founded in 2017 and is the only joint enterprise in China that simultaneously has mastered the production technology of zirconia and alumina ceramic materials. The zirconia ceramic joint caput femoris has officially entered the special approval procedure for innovative medical devices of NMPA, which fundamentally breaks the technological monopoly of foreign manufacturers, fills the gap in the market, and leads the new standard of international technology. As an integrated R&D and production enterprise of materials and devices, the company is dedicated to solving the problem of technology development bottleneck and accelerating the realization of localization substitution of the whole industrial chain.
Value Creation
Our goal is to create value that will contribute to the growth of enterprises, investors and the whole community.
International Cooperation Opportunities
We act as a long-term strategic partner for portfolio companies, introducing international cooperation opportunities.
Business Value Maximization
We help prepare a concrete IPO plan or conduct M&A to maximize business value.
Expanding Chinese Medical Market
We implement local and global cutting-edge biomedical products and technology to address medical needs in the Chinese community.
NEXT
Buyout
We seek to seize premium returns in Greater China’s mid-market buyout segment, where generational transitions and market transformations lead to attractive buyout opportunities.